What Happens if Latent TB is Not Treated
If latent tuberculosis infection (LTBI) is left untreated, approximately 5-10% of infected individuals will progress to active tuberculosis disease during their lifetime, with the majority developing disease within the first 5 years after initial infection 1, 2.
Progression Risk and Timeline
The natural history of untreated LTBI reveals concerning patterns:
- Overall lifetime risk: 5-15% of persons with documented LTBI will develop active TB disease 2
- Highest risk period: The majority of progression occurs within the first 5 years after initial infection, with approximately half of the lifetime risk occurring within the first 2 years 2, 3
- Population impact: Progression from untreated LTBI accounts for approximately 80% of U.S. TB disease cases 1
Risk Varies by Population
The likelihood of progression from latent to active disease is not uniform and depends heavily on host immune status and environmental factors 2. Among high-risk populations with positive tuberculosis testing, the incidence rates are substantially elevated:
Highest Risk Groups (per 1000 person-years):
- People living with HIV: 16.9-27.1 cases per 1000 person-years depending on test type 4
- Close TB contacts: 8.4-17.0 cases per 1000 person-years 4
- Immunocompromised patients: Including those on anti-TNF therapy, dialysis patients, transplant recipients, and patients with silicosis all show markedly elevated rates 2, 4
Comparison to General Population:
In the general population with positive tuberculin skin testing, the incidence is only 0.3 per 1000 person-years 4, demonstrating that the risk in high-risk populations is 30-90 times higher than in the general population.
Clinical Consequences of Progression
When untreated LTBI progresses to active TB disease, the consequences include:
- Mortality: Active TB carries significant mortality risk, particularly in immunocompromised individuals
- Morbidity: Pulmonary and extrapulmonary TB cause substantial organ damage and long-term complications
- Infectiousness: Patients become contagious, perpetuating transmission cycles
- Treatment burden: Active TB requires 6-9 months of multi-drug therapy versus 3-4 months for LTBI treatment
The Preventable Nature of This Risk
Treatment of LTBI is highly effective in preventing progression to active TB disease, with efficacy ranging from 60-90%, and protection lasting up to 19 years 2. This makes the decision to treat LTBI particularly compelling in high-risk populations where the benefits clearly outweigh the risks of treatment-related adverse events 2.
Key Clinical Pitfall:
The asymptomatic nature of LTBI creates a false sense of security. Patients and providers may underestimate the risk because there are no current symptoms, but the reservoir of one-third of the world's population with LTBI represents an enormous source for future active TB cases 5. This is why systematic testing and treatment in high-risk groups is strongly recommended 2.
The WHO End TB Strategy specifically targets LTBI management as essential for TB elimination, recognizing that without addressing this latent reservoir, active TB cases will continue to emerge 2, 6.